Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytek BioSciences

3.52
-0.2200-5.88%
Post-market: 3.520.00000.00%16:20 EDT
Volume:950.82K
Turnover:3.37M
Market Cap:450.90M
PE:-70.40
High:3.67
Open:3.60
Low:3.47
Close:3.74
Loading ...

Cytek Biosciences Price Target Maintained With a $6.00/Share by Stephens & Co.

Dow Jones
·
19 Mar

Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

GlobeNewswire
·
19 Mar

Open Lending Leads Our Trio Of Promising Penny Stocks

Simply Wall St.
·
11 Mar

Cytek Biosciences, Inc. (CTKB): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock?

Insider Monkey
·
08 Mar

Cytek Biosciences Is Maintained at Overweight by Piper Sandler

Dow Jones
·
04 Mar

Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)

TIPRANKS
·
04 Mar

Cytek Biosciences price target lowered to $8 from $8.25 at Piper Sandler

TIPRANKS
·
04 Mar

Cytek Biosciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
01 Mar

Cytek Biosciences Inc (CTKB) Q4 2024 Earnings Call Highlights: Strong International Growth and ...

GuruFocus.com
·
28 Feb

Cytek Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates

Zacks
·
28 Feb

Cytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52M

TIPRANKS
·
28 Feb

Cytek Biosciences Q4 EPS $0.07 Beats $0.05 Estimate, Sales $57.48M Miss $59.38M Estimate

Benzinga
·
28 Feb

BRIEF-Cytek Biosciences Q4 Revenue USD 57.5 Million Vs. IBES Estimate USD 59.4 Million

Reuters
·
28 Feb

Cytek Biosciences Q4 Adjusted Gross Margin 59%

THOMSON REUTERS
·
28 Feb

Cytek Biosciences Q4 Adjusted Ebitda USD 12.532 Million

THOMSON REUTERS
·
28 Feb

Cytek Biosciences Q4 Revenue USD 57.5 Million VS. Ibes Estimate USD 59.4 Million

THOMSON REUTERS
·
28 Feb

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

GlobeNewswire
·
28 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Feb

Goldman Sachs Downgrades Cytek Biosciences to Sell From Buy, Adjusts Price Target to $4.50 From $7

MT Newswires Live
·
31 Jan